Transgene S.a.

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

F. Hoffmann-La Roche Ag

Bioprocess Pty Ltd.

Geneviève Inchauspe

Perrine Martin

Nathalie Silvestre

Alfred M Prince

Anne Fournillier

Doris Schmitt

Nourredine Himoudi

Alexei Evlachev

Glaucia Paranhos-Baccala

Thierry Delair

Yasemin Ataman-Onal

Bernard Verrier

François Penin

Pascale Jeannin

Jean-Daniel Abraham

Maria Dimitrova-Tchomakov

Marie Parnot

Suzanne Zebedee

Laurence Chatel

Marc S Nasoff

The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

Composition for treating HBV infection

The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: It further relates to the bioresorbable microparticles thus obtained and use thereof in diagnosis and therapy.

Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof

The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.

Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus

The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N1, a peptide B having at least the amino acid sequence of SEQ ID N45, a peptide C having at least the amino acid sequence of SEQ ID N127, a peptide D having at least the amino acid sequence of SEQ. ID N174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Peptide compositions and their use against HCV

Growing community of inventors

Lyons, France

Geneviève Inchauspe